GlaxoSmithKline (($GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is launching a new clinical study titled A ...

Depemokimab’s PDUFA date is set for December 16, 2025, with FDA reviewing two indications. Phase 3 trials showed significant improvements in nasal polyp size and obstruction. Tonight: Get a FREE TRADE ...

Depemokimab has high binding affinity and potency for IL-5. Eosinophils fell by 83% and 82% with treatment in the two trials. The treatment and placebo groups had similar rates and types of adverse ...

GSK’s GSK two-phase III studies, which evaluated depemokimab for treating severe asthma characterized by type II inflammation, met their primary endpoints. The primary endpoints of the SWIFT-1 and ...

A Prescription Drug User Fee Act target date of December 16, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for review the Biologics License Application ...

GSK plc GSK announced positive data from the phase III ANCHOR-1 and ANCHOR-2 studies, which evaluated its pipeline candidate, depemokimab, for treating adults with chronic rhinosinusitis with nasal ...

GSK to showcase new research from its broad respiratory portfolio at the European Respiratory Society Congress 2025: London, UK Wednesday, September 17, 2025, 11:00 Hrs [IST] GSK ...

The ultra-long acting investigational biologic is administered once every 6 months as a subcutaneous injection. Depemokimab reduced the rate of exacerbations in patients with severe asthma with type 2 ...

GSK said that it had positive results from phase III trials of depemokimab, aimed at assessing the drug's efficacy and safety in adults and adolescents with severe asthma. The British pharmaceutical ...

GSK's phase 3 trials ANCHOR-1 and ANCHOR-2 met co-primary endpoints for treating CRSwNP with depemokimab. Adverse event rates were similar between depemokimab and placebo in the trials. Ready to turn ...